US Stock Futures Signal Lower Start On Wall Street

Loading...
Loading...
Pre-open movers
US stock futures traded lower in early pre-market trade. The pending home sales index for May will be released at 10:00 a.m. ET, while the Dallas Fed general activity index for June will be released at 10:30 a.m. ET. Futures for the Dow Jones Industrial Average tumbled 198 points to 17,675.0, while the Standard & Poor's 500 index futures fell 24.30 points to 2,071.45. Futures for the Nasdaq 100 index dipped 58.30 points to 4,422.20.
A Peek Into Global Markets
European markets were lower today, with the Spanish Ibex Index dipping 3.89 percent, STOXX Europe 600 Index falling 2.50 percent and German DAX 30 index dropping 1.23 percent. French CAC 40 Index declined 3.56 percent and London's FTSE 100 Index fell 1.61 percent. In Asian markets, Japan's Nikkei Stock Average fell 2.88 percent, Hong Kong's Hang Seng Index slipped 2.61 percent, China's Shanghai Composite Index dipped 3.34 percent and India's BSE Sensex slipped 0.60 percent.
Broker Recommendation
Analysts at Deutsche Bank downgraded
Macy's, Inc. M
from Buy to Sell and lowered the price target from $71.00 to $63.00. Macy's shares rose 1 percent to close at $69.86 on Friday.
Breaking news
  • Can-Fite BioPharma Ltd. CANF today reported further progress in its continuing preclinical program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow the initiation of a Phase I clinical study. To read the full news, click here.
  • RedHill Biopharma Ltd. RDHL today announced that it has initiated a Phase I/II clinical study in the U.S. evaluating ABC294640 in patients with refractory/relapsed diffuse large B-cell lymphoma (DLBCL). To read the full news, click here.
  • Sarepta Therapeutics, Inc. SRPT today announced the completion of the rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for eteplirsen on June 26, 2015. Eteplirsen, the Company's lead drug candidate, targets the underlying cause of Duchenne muscular dystrophy and is designed to enable the production of a functional internally truncated dystrophin protein in patients with mutations amenable to exon 51 skipping. To read the full news, click here.
  • Vitae Pharmaceuticals, Inc. VTAE today announced top-line clinical efficacy results from the metformin arm of an ongoing Phase 2 proof-of-concept clinical trial of BI187004/VTP-34072 in the treatment of overweight type 2 diabetic patients. To read the full news, click here.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsConsumer DiscretionaryDepartment StoresDeutsche BankUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...